First Patients Dosed in Alphyn Biologics’ Phase 2 Trial of First-in-Class Topical Therapeutic for Molluscum Contagiosum

Press Release

First Patients Dosed in Alphyn Biologics’ Phase 2 Trial of First-in-Class Topical Therapeutic for Molluscum Contagiosum NEWS PROVIDED BY Alphyn Biologics Feb 18, 2026, 07:30 ET New program expands pipeline derived from Alphyn’s proprietary multi-target drug platform ANNAPOLIS, Md., Feb. 18, 2026 /PRNewswire/ — Alphyn Biologics, Inc., a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®,…

Masters of Pediatric Dermatology 2026 Poster Presentation: S. aureus Contribution to the Etiology of Pediatric Atopic Dermatitis

Clinical Presentations

Masters of Pediatric Dermatology 2026 Poster Presentation: S. aureus Contribution to the Etiology of Pediatric Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics February 5, 2026, 00:00 ET CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195

Alphyn Closes $25M Oversubscribed Series B Financing Round to Advance Dermatology Pipeline

Press Release

Alphyn Closes $25M Oversubscribed Series B Financing Round to Advance Dermatology Pipeline NEWS PROVIDED BY Alphyn Biologics Dec 12, 2025, 07:30 ET Financing funds the global Phase 2b clinical trial in atopic dermatitis and Phase 2 clinical program in molluscum contagiosum ANNAPOLIS, Md., Dec. 12, 2025 /PRNewswire/ — Alphyn Biologics, Inc., a clinical-stage dermatology company developing…

Alphyn Expands Patent Estate with New U.S. Patent for Atopic Dermatitis Therapeutic

Press Release

Alphyn Expands Patent Estate with New U.S. Patent for Atopic Dermatitis Therapeutic NEWS PROVIDED BY Alphyn Biologics Oct 27, 2025, 07:30 ET Patent covers active pharmaceutical ingredient with protection until 2041 ANNAPOLIS, Md., Oct. 27, 2025 /PRNewswire/ — Alphyn, a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®, announced today that the U.S. Patent and Trademark Office…

15th Georg RAJKA ISAD Presentation: Zabalafin Hydrogel – A Novel Topical Botanical Drug That Addresses the Four Demons of Atopic Dermatitis

Clinical Presentations

15th Georg RAJKA International Symposium on Atopic Dermatitis Presentation: Zabalafin Hydrogel – A Novel Topical Botanical Drug That Addresses the Four Demons of Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics October 27, 2025, 07:30 ET 1168_Neal-KOLLER_phase-2b-trial-of-zabalafin-hydrogel-a-novel-topical-botanical-drug-that-addresses-the-four-demons-of-atopic-dermatitis CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195